Medicalsystem Biotechnology Co., Ltd (SHE:300439)
China · Delayed Price · Currency is CNY 10.25
+0.10 (0.99%)
Feb 4, 2026, 3:04 PM CST
SHE:300439 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 1,457 | 1,728 | 1,875 | 2,473 | 2,238 | 2,292 |
Other Revenue | 14.7 | 14.7 | 11.01 | 16.37 | 13.6 | 10.25 |
| 1,471 | 1,742 | 1,886 | 2,489 | 2,252 | 2,302 | |
Revenue Growth (YoY) | -19.24% | -7.61% | -24.23% | 10.55% | -2.19% | -26.53% |
Cost of Revenue | 892.9 | 972.72 | 1,060 | 1,552 | 1,348 | 1,472 |
Gross Profit | 578.48 | 769.7 | 825.44 | 937.49 | 903.98 | 830.24 |
Selling, General & Admin | 403.48 | 403.11 | 440.58 | 475.15 | 475.35 | 445.31 |
Research & Development | 134.83 | 146.47 | 149.8 | 171.78 | 150.68 | 135.48 |
Other Operating Expenses | 16.88 | -0.78 | 8.36 | 12.94 | 17.5 | -17.88 |
Operating Expenses | 548.29 | 529.07 | 594.47 | 700.85 | 665.38 | 564.58 |
Operating Income | 30.19 | 240.63 | 230.97 | 236.63 | 238.6 | 265.67 |
Interest Expense | -2.16 | -2.52 | -10.66 | -15.63 | -29.26 | -55.14 |
Interest & Investment Income | 7.85 | 24.81 | 28.2 | 11.18 | 6.69 | 19.61 |
Currency Exchange Gain (Loss) | -2.56 | -2.56 | -0.64 | 4.34 | -2.9 | -0.45 |
Other Non Operating Income (Expenses) | -4.02 | 0.85 | 27.01 | -13.24 | -3.67 | 176.61 |
EBT Excluding Unusual Items | 29.31 | 261.21 | 274.87 | 223.27 | 209.46 | 406.3 |
Impairment of Goodwill | - | - | - | - | -3.89 | -6.71 |
Gain (Loss) on Sale of Investments | -10.6 | -11.11 | -3.6 | -9.69 | -15.98 | -55.62 |
Gain (Loss) on Sale of Assets | -0.66 | -0.67 | -0.78 | -0.32 | 0.48 | 3.22 |
Asset Writedown | -3.13 | -2.2 | -10.87 | -13.1 | -0.13 | -0.07 |
Other Unusual Items | 50.85 | 20.11 | 27.52 | 23.15 | 28.3 | -0.08 |
Pretax Income | 80.79 | 282.36 | 295.68 | 223.31 | 218.24 | 347.05 |
Income Tax Expense | -17.45 | 19.69 | 36.18 | 18.1 | 28.08 | 53.48 |
Earnings From Continuing Operations | 98.24 | 262.67 | 259.5 | 205.2 | 190.15 | 293.57 |
Minority Interest in Earnings | -4.07 | -4.68 | -2.95 | -6.68 | -10.66 | 5.91 |
Net Income | 94.17 | 258 | 256.55 | 198.53 | 179.49 | 299.48 |
Net Income to Common | 94.17 | 258 | 256.55 | 198.53 | 179.49 | 299.48 |
Net Income Growth | -62.48% | 0.56% | 29.23% | 10.61% | -40.07% | - |
Shares Outstanding (Basic) | 385 | 385 | 383 | 382 | 374 | 344 |
Shares Outstanding (Diluted) | 385 | 385 | 383 | 382 | 374 | 344 |
Shares Change (YoY) | 0.42% | 0.56% | 0.30% | 2.10% | 8.59% | 0.24% |
EPS (Basic) | 0.24 | 0.67 | 0.67 | 0.52 | 0.48 | 0.87 |
EPS (Diluted) | 0.24 | 0.67 | 0.67 | 0.52 | 0.48 | 0.87 |
EPS Growth | -62.63% | - | 28.85% | 8.33% | -44.81% | - |
Free Cash Flow | 115.69 | -22.73 | 353.16 | 261.53 | 313.67 | 528.64 |
Free Cash Flow Per Share | 0.30 | -0.06 | 0.92 | 0.69 | 0.84 | 1.53 |
Dividend Per Share | 0.135 | 0.135 | 0.134 | 0.105 | 0.095 | 0.157 |
Dividend Growth | 0.75% | 0.75% | 27.62% | 10.53% | -39.38% | - |
Gross Margin | 39.31% | 44.17% | 43.77% | 37.66% | 40.15% | 36.07% |
Operating Margin | 2.05% | 13.81% | 12.25% | 9.51% | 10.60% | 11.54% |
Profit Margin | 6.40% | 14.81% | 13.60% | 7.98% | 7.97% | 13.01% |
Free Cash Flow Margin | 7.86% | -1.30% | 18.73% | 10.51% | 13.93% | 22.96% |
EBITDA | 247.25 | 430.13 | 383.73 | 406.75 | 412.01 | 439.18 |
EBITDA Margin | 16.80% | 24.69% | 20.35% | 16.34% | 18.30% | 19.08% |
D&A For EBITDA | 217.06 | 189.5 | 152.76 | 170.12 | 173.4 | 173.52 |
EBIT | 30.19 | 240.63 | 230.97 | 236.63 | 238.6 | 265.67 |
EBIT Margin | 2.05% | 13.81% | 12.25% | 9.51% | 10.60% | 11.54% |
Effective Tax Rate | - | 6.97% | 12.24% | 8.11% | 12.87% | 15.41% |
Revenue as Reported | 1,471 | 1,742 | 1,886 | 2,489 | 2,252 | 2,302 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.